Clinical and biological parameters in CMML and MDS patients diagnosed according to 2016 revised WHO criteria
| . | Total CMML . | CMML-0 . | CMML-1 . | CMML-2 . | Total MDS . | CMML-like MDS . | Other MDS . |
|---|---|---|---|---|---|---|---|
| Patients, n (%) | 152 (100) | 62 (41) | 66 (43) | 24 (16) | 84 (100) | 29 (35) | 55 (65) |
| Age, y | 74 ± 10 | 72 ± 11 | 75 ± 9 | 74 ± 9 | 72 ± 10 | 70 ± 11 | 73 ± 10 |
| Male, n (%) | 101 (66) | 42 (68) | 46 (70) | 13 (54) | 49 (58) | 14 (48) | 35 (64) |
| Hb, g/dL | 11.7 ± 2.5 | 12.1 ± 2.4 | 11.6 ± 2.6 | 10.8 ± 2.2 | 10.8 ± 2.1 | 10.0 ± 1.7 | 11.2 ± 2.1 |
| Platelets, ×109/L | 157 ± 122 | 204 ± 143 | 132 ± 93 | 104 ± 90 | 145 ± 104 | 148 ± 110 | 143 ± 102 |
| WBC, ×109/L | 11.9 ± 8.1 | 10.7 ± 6.1 | 12.2 ± 8.7 | 14.0 ± 10.5 | 5.0 ± 2.9 | 6.1 ± 3.9 | 4.4 ± 2.0 |
| Neutrophils, ×109/L | 6.4 ± 5.2 | 6.1 ± 4.3 | 6.5 ± 5.9 | 6.8 ± 5.6 | 3.0 ± 2.6 | 4.0 ± 3.5 | 2.5 ± 1.7 |
| Monocytes, ×109/L | 2.8 ± 2.4 | 2.2 ± 1.6 | 3.1 ± 2.7 | 3.6 ± 2.8 | 0.5 ± 0.2 | 0.6 ± 0.2 | 0.4 ± 0.2 |
| Blood monocytes, % | 24 ± 10 | 22 ± 11 | 25 ± 9 | 27 ± 13 | 11 ± 8 | 11 ± 8 | 11 ± 8 |
| Marrow monocytes, % | 11 ± 6 | 9 ± 5 | 12 ± 7 | 13 ± 7 | 4 ± 4 | 6 ± 4 | 4 ± 3 |
| Marrow blasts, % | 6 ± 4 | 2 ± 1 | 7 ± 2 | 14 ± 3 | 5 ± 4 | 6 ± 4 | 5 ± 4 |
| Myelodysplasic form, n (%) | 104 (68) | 44 (71) | 46 (70) | 14 (58) | 83 (99) | 28 (97) | 55 (100) |
| Mean MO1 fraction, % | 96.2 ± 3.1 | 96.0 ± 3.7 | 96.2 ± 3.0 | 96.9 ± 1.3 | 88.0 ± 10.3 | 96.7 ± 1.4 | 83.3 ± 10.1 |
| Patients with MO1 ≥94%, n (%) | 141 (93) | 55 (89) | 62 (94) | 24 (100) | 29 (35) | 29 (100) | 0 (0) |
| De novo diagnosis, n (%) | 112 (74) | 54 (87) | 45 (68) | 13 (54) | — | — | — |
| IPSS-R, n (%) | 123 (81) | 47 (76) | 55 (83) | 21 (88) | 74 (88) | 28 (97) | 46 (84) |
| Very low IPSS-R, n (%) | 22 (18) | 22 (47) | 0 (0) | 0 (0) | 14 (19) | 3 (11) | 11 (24) |
| Low IPSS-R, n (%) | 46 (37) | 20 (42) | 25 (45) | 1 (5) | 20 (27) | 8 (29) | 12 (26) |
| Intermediate IPSS-R, n (%) | 35 (29) | 5 (11) | 22 (40) | 8 (38) | 30 (40) | 14 (50) | 16 (35) |
| High IPSS-R, n (%) | 17 (14) | 0 (0) | 6 (11) | 11 (52) | 5 (7) | 1 (3) | 4 (9) |
| Very high IPSS-R, n (%) | 3 (2) | 0 (0) | 2 (4) | 1 (5) | 5 (7) | 2 (7) | 3 (6) |
| CPSS, n (%) | 124 (82) | 48 (77) | 55 (83) | 21 (88) | — | — | — |
| Low CPSS, n (%) | 54 (44) | 24 (50) | 30 (54) | 0 (0) | — | — | — |
| Intermediate-1 CPSS, n (%) | 36 (29) | 16 (33) | 13 (24) | 7 (33) | — | — | — |
| Intermediate-2 CPSS, n (%) | 30 (24) | 8 (17) | 12 (22) | 10 (48) | — | — | — |
| High CPSS, n (%) | 4 (3) | 0 (0) | 0 (0) | 4 (19) | — | — | — |
| . | Total CMML . | CMML-0 . | CMML-1 . | CMML-2 . | Total MDS . | CMML-like MDS . | Other MDS . |
|---|---|---|---|---|---|---|---|
| Patients, n (%) | 152 (100) | 62 (41) | 66 (43) | 24 (16) | 84 (100) | 29 (35) | 55 (65) |
| Age, y | 74 ± 10 | 72 ± 11 | 75 ± 9 | 74 ± 9 | 72 ± 10 | 70 ± 11 | 73 ± 10 |
| Male, n (%) | 101 (66) | 42 (68) | 46 (70) | 13 (54) | 49 (58) | 14 (48) | 35 (64) |
| Hb, g/dL | 11.7 ± 2.5 | 12.1 ± 2.4 | 11.6 ± 2.6 | 10.8 ± 2.2 | 10.8 ± 2.1 | 10.0 ± 1.7 | 11.2 ± 2.1 |
| Platelets, ×109/L | 157 ± 122 | 204 ± 143 | 132 ± 93 | 104 ± 90 | 145 ± 104 | 148 ± 110 | 143 ± 102 |
| WBC, ×109/L | 11.9 ± 8.1 | 10.7 ± 6.1 | 12.2 ± 8.7 | 14.0 ± 10.5 | 5.0 ± 2.9 | 6.1 ± 3.9 | 4.4 ± 2.0 |
| Neutrophils, ×109/L | 6.4 ± 5.2 | 6.1 ± 4.3 | 6.5 ± 5.9 | 6.8 ± 5.6 | 3.0 ± 2.6 | 4.0 ± 3.5 | 2.5 ± 1.7 |
| Monocytes, ×109/L | 2.8 ± 2.4 | 2.2 ± 1.6 | 3.1 ± 2.7 | 3.6 ± 2.8 | 0.5 ± 0.2 | 0.6 ± 0.2 | 0.4 ± 0.2 |
| Blood monocytes, % | 24 ± 10 | 22 ± 11 | 25 ± 9 | 27 ± 13 | 11 ± 8 | 11 ± 8 | 11 ± 8 |
| Marrow monocytes, % | 11 ± 6 | 9 ± 5 | 12 ± 7 | 13 ± 7 | 4 ± 4 | 6 ± 4 | 4 ± 3 |
| Marrow blasts, % | 6 ± 4 | 2 ± 1 | 7 ± 2 | 14 ± 3 | 5 ± 4 | 6 ± 4 | 5 ± 4 |
| Myelodysplasic form, n (%) | 104 (68) | 44 (71) | 46 (70) | 14 (58) | 83 (99) | 28 (97) | 55 (100) |
| Mean MO1 fraction, % | 96.2 ± 3.1 | 96.0 ± 3.7 | 96.2 ± 3.0 | 96.9 ± 1.3 | 88.0 ± 10.3 | 96.7 ± 1.4 | 83.3 ± 10.1 |
| Patients with MO1 ≥94%, n (%) | 141 (93) | 55 (89) | 62 (94) | 24 (100) | 29 (35) | 29 (100) | 0 (0) |
| De novo diagnosis, n (%) | 112 (74) | 54 (87) | 45 (68) | 13 (54) | — | — | — |
| IPSS-R, n (%) | 123 (81) | 47 (76) | 55 (83) | 21 (88) | 74 (88) | 28 (97) | 46 (84) |
| Very low IPSS-R, n (%) | 22 (18) | 22 (47) | 0 (0) | 0 (0) | 14 (19) | 3 (11) | 11 (24) |
| Low IPSS-R, n (%) | 46 (37) | 20 (42) | 25 (45) | 1 (5) | 20 (27) | 8 (29) | 12 (26) |
| Intermediate IPSS-R, n (%) | 35 (29) | 5 (11) | 22 (40) | 8 (38) | 30 (40) | 14 (50) | 16 (35) |
| High IPSS-R, n (%) | 17 (14) | 0 (0) | 6 (11) | 11 (52) | 5 (7) | 1 (3) | 4 (9) |
| Very high IPSS-R, n (%) | 3 (2) | 0 (0) | 2 (4) | 1 (5) | 5 (7) | 2 (7) | 3 (6) |
| CPSS, n (%) | 124 (82) | 48 (77) | 55 (83) | 21 (88) | — | — | — |
| Low CPSS, n (%) | 54 (44) | 24 (50) | 30 (54) | 0 (0) | — | — | — |
| Intermediate-1 CPSS, n (%) | 36 (29) | 16 (33) | 13 (24) | 7 (33) | — | — | — |
| Intermediate-2 CPSS, n (%) | 30 (24) | 8 (17) | 12 (22) | 10 (48) | — | — | — |
| High CPSS, n (%) | 4 (3) | 0 (0) | 0 (0) | 4 (19) | — | — | — |
CMML patients were subdivided into 3 groups, CMML-0, CMML-1, and CMML-2, according to the WHO classification, and MDS patients into 2 groups according to presence or absence of MO1 accumulation ≥94% in the peripheral blood at diagnosis. All parameters are mean ± standard deviation, unless otherwise specified. We indicate the mean MO1 fraction in each subgroup of patients and the percentage of patients whose MO1 fraction was equal or higher than 94%, defined as “Patients with MO1 ≥94%.”